Market Overview
Neovascular age-related macular degeneration (nAMD) is a chronic eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is one of the leading causes of vision loss in elderly populations. The neovascular form of AMD occurs when abnormal blood vessels grow under the retina, leaking fluid or blood and damaging retinal cells. As the global population ages, the incidence of AMD, particularly the neovascular type, is rising, leading to a growing demand for effective treatment options. Neovascular AMD significantly impacts the quality of life of patients, making early detection and treatment crucial to preventing further vision loss. This market is evolving rapidly with advancements in pharmacological treatments and innovations in drug delivery systems.
The neovascular AMD treatment market is crucial for improving the quality of life for millions of elderly patients worldwide. The rise of novel therapies, including anti-VEGF (vascular endothelial growth factor) agents, has significantly transformed the way nAMD is treated. Given the global aging population, coupled with the increasing incidence of neovascular AMD, the market is poised for substantial growth. The market is primarily driven by advances in biologics, which target the root cause of the disease, reducing disease progression and vision loss.
Market Size and Share
The neovascular age-related macular degeneration treatment market was valued at USD 11 billion in 2024 across the seven major markets (7MM)—the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. With the aging population and rising incidence rates of neovascular AMD, the market is projected to expand at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2034. This growth trajectory will result in a market value of approximately USD 21.1 billion by 2034. The increasing demand for advanced treatment options and innovative drug formulations, combined with expanding healthcare infrastructure, is driving this growth.
Market Trends
- Increasing Adoption of Anti-VEGF Therapy
Anti-VEGF therapies, such as ranibizumab, aflibercept, and bevacizumab, are leading the market in the treatment of neovascular AMD. These biologic drugs inhibit the VEGF protein, which is responsible for abnormal blood vessel growth. The widespread adoption of anti-VEGF agents has significantly improved treatment outcomes, leading to an increase in the market share of these therapies. New formulations with longer dosing intervals are further contributing to the growth of this segment. - Emerging Therapies and Innovations
Research into new treatment modalities for neovascular AMD is thriving. Next-generation anti-VEGF therapies, including brolucizumab and faricimab, offer improved efficacy and longer treatment intervals. The continuous development of these therapies, alongside innovations in drug delivery systems such as gene therapy and sustained-release devices, is expected to further revolutionize the treatment landscape. These advancements will likely drive the market’s growth and expand the treatment options available to patients. - Shift Towards Personalized Medicine
Personalized medicine is gaining traction in the treatment of neovascular AMD. By tailoring treatment plans based on patient-specific factors, such as genetic profiles and disease stage, clinicians can achieve better outcomes. This approach not only helps optimize the therapeutic benefit but also minimizes side effects. As biomarkers and genetic tests become more accessible, personalized treatments will play an increasingly important role in the management of neovascular AMD. - Improved Accessibility and Availability
Increased accessibility to neovascular AMD treatments is another key trend shaping the market. The expansion of retail and online pharmacies is making treatment more readily available to patients, particularly in rural and underserved areas. Additionally, greater healthcare funding and government support for eye health initiatives are helping improve access to essential therapies, further driving market growth.
Market Analysis
- Drug Type Segmentation: The Rise of Anti-VEGF Agents
Anti-VEGF therapies are the cornerstone of neovascular AMD treatment. Ranibizumab, aflibercept, and bevacizumab have been widely used for treating nAMD and have a significant market share. Their ability to inhibit the abnormal blood vessel growth characteristic of nAMD has revolutionized the treatment landscape. The emergence of next-generation therapies, such as brolucizumab and faricimab, is set to further strengthen the position of anti-VEGF agents in the market. - Disease Type Segmentation: Focus on Wet AMD
Neovascular AMD is often referred to as wet AMD, distinguishing it from dry AMD, which has a slower progression. Wet AMD is more prevalent in patients over the age of 60 and causes rapid vision loss. Treatment for wet AMD focuses on halting or slowing the abnormal blood vessel growth through anti-VEGF therapies. The dominance of wet AMD cases in the market underscores the importance of targeted therapies in disease management. - Age Group Segmentation: Elderly Population at Risk
Neovascular AMD predominantly affects people over the age of 60, with the highest incidence in those over 80. As the global population continues to age, the number of people susceptible to neovascular AMD is growing. Treatments tailored to this age group, such as long-acting injections and less frequent dosing schedules, are being developed to meet the needs of elderly patients, driving market growth. - Gender Segmentation: Impact on Both Genders
While both men and women are affected by neovascular AMD, studies indicate that the disease may be slightly more prevalent in women. This has implications for treatment strategies, as women may require tailored interventions based on gender-specific biological factors. Understanding these differences will allow for more targeted and effective treatments for both genders in the coming years.
Scope of the Report
This report covers a detailed analysis of the neovascular age-related macular degeneration (AMD) treatment market, including key trends, market dynamics, and future projections from 2025 to 2034. The report breaks down the market by drug type, disease type, age group, disease stage, gender, and distribution channel. It also provides a regional analysis of the seven major markets (7MM) and examines the competitive landscape, key players, and emerging trends.
Historical and Forecast Trends
Historically, the treatment of neovascular AMD has involved the use of anti-VEGF agents, which have demonstrated significant efficacy in halting disease progression and preserving vision. The forecast period from 2025 to 2034 will witness continued growth in the market, driven by the development of novel therapies that provide longer treatment intervals and improved efficacy. The introduction of personalized medicine and combination therapies will also play a key role in shaping the future of AMD treatment.
Industry Drivers and Constraints
Key drivers of the market include the increasing prevalence of neovascular AMD, technological advancements in drug development, and the growing aging population. On the other hand, challenges such as high treatment costs, limited access to healthcare in certain regions, and the risk of side effects associated with long-term use of biologic therapies may constrain market growth. Addressing these challenges will be crucial for the future of the market.
Market Growth
The neovascular AMD treatment market is expected to grow at a CAGR of 7.5% from 2025 to 2034, driven by advancements in treatment technologies and increasing demand for therapies that provide better outcomes and improved quality of life. The ongoing development of new biologics, coupled with the expansion of healthcare access, will continue to propel market growth.
Get a Free Sample Report with a Table of Contents
Recent Developments & Challenges
- Introduction of Brolucizumab
The approval of brolucizumab, a next-generation anti-VEGF agent, marked a significant milestone in the treatment of neovascular AMD. Its ability to offer longer treatment intervals and enhanced efficacy has made it a promising option for patients, contributing to the market's growth. - Faricimab and Dual Mechanism
Faricimab, a promising anti-VEGF therapy, works through a dual mechanism of action, targeting both VEGF and angiopoietin-2. This dual approach has shown promising results in clinical trials, positioning faricimab as a strong contender in the neovascular AMD treatment market. - Expansion of Access to Treatment
Efforts to improve access to neovascular AMD treatments, particularly in developing regions, have gained traction. Government policies and healthcare initiatives aimed at reducing the cost of treatment are expected to expand the patient base and drive market growth. - Regulatory Challenges
While new therapies are advancing, regulatory hurdles in the approval process for novel treatments can delay market entry. Ensuring that these therapies meet safety and efficacy standards remains a critical challenge for the industry.
Key Players
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is a global leader in the neovascular AMD treatment market, offering ranibizumab (Lucentis) as one of the most widely used therapies for wet AMD. The company is at the forefront of biologic drug development and continues to expand its pipeline with newer anti-VEGF agents like faricimab, further solidifying its position in the market.
Bausch & Lomb
Bausch & Lomb, a key player in the ophthalmic industry, has contributed significantly to the neovascular AMD treatment market with its drug, ranibizumab. The company’s ongoing research in eye care and treatments for retinal diseases positions it as a leader in the fight against AMD.
Novartis AG
Novartis AG is another major player in the neovascular AMD treatment market. Its aflibercept (Eylea) is a widely used anti-VEGF agent that has shown significant efficacy in treating wet AMD. Novartis continues to innovate in the field of ophthalmology with ongoing clinical trials and product development.
Pfizer, Inc.
Pfizer, Inc. has established itself as a key player in the neovascular AMD market, primarily through its involvement in the development of advanced biologic therapies. With a strong focus on research and development, Pfizer is exploring new treatment options and delivery methods for AMD.
Other Companies
Other notable companies in the neovascular AMD treatment market include AbbVie Inc., Santen Pharmaceutical Co., Ltd., Ophthotech Corporation, Alimera Sciences, GSK plc, Bayer AG, and more. These companies are continuously working to innovate and expand their portfolios in the ophthalmic space.
FAQs
What is neovascular AMD?
Neovascular age-related macular degeneration (nAMD) is a form of AMD characterized by the growth of abnormal blood vessels in the retina, leading to rapid vision loss.
What are the main treatments for neovascular AMD?
The primary treatments for neovascular AMD include anti-VEGF therapies, such as ranibizumab, aflibercept, and bevacizumab, which aim to inhibit the abnormal growth of blood vessels in the retina.
What is the expected market growth for neovascular AMD treatments?
The neovascular AMD treatment market is expected to grow at a CAGR of 7.5%, reaching USD 21.1 billion by 2034.
What are the challenges in the neovascular AMD treatment market?
Key challenges include the high cost of treatment, limited access to healthcare in some regions, and regulatory hurdles in approving new therapies.
Read Our Blogs
Global Vessel Sealing Device Market: Top 9 Leading Providers & Innovations
